Cannlabs Inc
CannLabs, Inc. provides cannabis testing laboratory services in the United States. Its testing services include potency testing, residual solvent analysis, microbiological testing, pesticide testing, heavy metals testing, nutrient analysis, terpenes analysis, shelf-life/stability studies, gene expression testing, and genotyping/phenotyping testing. The company also offers data/analytics and consu… Read more
Cannlabs Inc (CANL) - Net Assets
Latest net assets as of December 2022: $2.40 Million USD
Based on the latest financial reports, Cannlabs Inc (CANL) has net assets worth $2.40 Million USD as of December 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.25 Million) and total liabilities ($846.12K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.40 Million |
| % of Total Assets | 73.96% |
| Annual Growth Rate | 31.04% |
| 5-Year Change | N/A |
| 10-Year Change | 116881.89% |
| Growth Volatility | 1813.31 |
Cannlabs Inc - Net Assets Trend (2009–2022)
This chart illustrates how Cannlabs Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cannlabs Inc (2009–2022)
The table below shows the annual net assets of Cannlabs Inc from 2009 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $2.40 Million | +9.54% |
| 2021-12-31 | $2.19 Million | +14.30% |
| 2020-12-31 | $1.92 Million | +3.05% |
| 2019-12-31 | $1.86 Million | +214.33% |
| 2018-12-31 | $-1.63 Million | 0.00% |
| 2017-12-31 | $-1.63 Million | 0.00% |
| 2016-12-31 | $-1.63 Million | 0.00% |
| 2014-12-31 | $-1.63 Million | -1660.96% |
| 2013-12-31 | $104.36K | +4980.67% |
| 2012-12-31 | $2.05K | -93.11% |
| 2011-12-31 | $29.83K | -55.33% |
| 2010-12-31 | $66.78K | -6.62% |
| 2009-12-31 | $71.51K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cannlabs Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 379701500.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $2.64 Million | 109.97% |
| Common Stock | $420.45K | 17.50% |
| Total Equity | $2.40 Million | 100.00% |
Cannlabs Inc Competitors by Market Cap
The table below lists competitors of Cannlabs Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KAL Energy Inc
PINK:KALG
|
$0.92 |
|
Ijj Corporation
PINK:IJJP
|
$0.92 |
|
ComF5 International Inc
PINK:CMFV
|
$0.92 |
|
USCorp
PINK:USCS
|
$0.92 |
|
Cal-Bay Intl Inc
PINK:CBYI
|
$0.92 |
|
Capital Financial Gl
PINK:CFGX
|
$0.92 |
|
Evolution Technology Resources Inc
PINK:ETKR
|
$0.92 |
|
FlexPower Inc
PINK:FLXP
|
$0.92 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cannlabs Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 2,193,637 to 2,402,808, a change of 209,171 (9.5%).
- Net income of 869,171 contributed positively to equity growth.
- Other factors decreased equity by 660,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $869.17K | +36.17% |
| Other Changes | $-660.00K | -27.47% |
| Total Change | $- | 9.54% |
Book Value vs Market Value Analysis
This analysis compares Cannlabs Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | $0.00 | $0.00 | x |
| 2010-12-31 | $0.00 | $0.00 | x |
| 2011-12-31 | $0.00 | $0.00 | x |
| 2012-12-31 | $0.00 | $0.00 | x |
| 2013-12-31 | $0.00 | $0.00 | x |
| 2014-12-31 | $0.00 | $0.00 | x |
| 2016-12-31 | $0.00 | $0.00 | x |
| 2017-12-31 | $0.00 | $0.00 | x |
| 2018-12-31 | $0.00 | $0.00 | x |
| 2019-12-31 | $0.03 | $0.00 | x |
| 2020-12-31 | $0.00 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
| 2022-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cannlabs Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 36.17%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.79%
- • Asset Turnover: 1.35x
- • Equity Multiplier: 1.35x
- Recent ROE (36.17%) is above the historical average (-61856.16%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -65.28% | -328.93% | 0.07x | 2.66x | $-53.83K |
| 2010 | -119.41% | -164.41% | 0.32x | 2.29x | $-86.41K |
| 2011 | -520.70% | -961.07% | 0.18x | 2.93x | $-158.30K |
| 2012 | -1352.24% | -19.00% | 4.57x | 15.58x | $-27.98K |
| 2013 | -75.73% | -93.75% | 0.40x | 2.01x | $-89.47K |
| 2014 | -200533.92% | -116.08% | 1.04x | 1667.88x | $-1.58 Million |
| 2016 | -200533.92% | -116.08% | 1.04x | 1667.88x | $-1.58 Million |
| 2017 | -200533.92% | -116.08% | 1.04x | 1667.88x | $-1.58 Million |
| 2018 | -200533.92% | -116.08% | 1.04x | 1667.88x | $-1.58 Million |
| 2019 | 43.15% | 32.16% | 1.14x | 1.17x | $617.34K |
| 2020 | 27.13% | 18.83% | 1.02x | 1.41x | $328.66K |
| 2021 | 32.49% | 22.41% | 1.07x | 1.36x | $493.43K |
| 2022 | 36.17% | 19.79% | 1.35x | 1.35x | $628.89K |
Industry Comparison
This section compares Cannlabs Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cannlabs Inc (CANL) | $2.40 Million | -65.28% | 0.35x | $0.92 |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |